Member access

4-Traders Homepage  >  Shares  >  London Stock Exchange  >  SkyePharma PLC    SKP   GB00B3BFNB64

SKYEPHARMA PLC (SKP)

8
Delayed Quote. Delayed London Stock Exchange - 10/24 11:35:04 am
369 GBp   +4.68%
10/09 SKYEPHARMA : Says Sales Momentum Has Continued Since August
09/08 SKYEPHARMA : Partner Announces Phase III Flutiform Study Results
08/23 SKYEPHARMA : Holding(s) in Company
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/20/2014 10/21/2014 10/22/2014 10/23/2014 10/24/2014 Date
340(c) 338(c) 339.75(c) 352.5(c) 369(c) Last
1 236 114 68 990 186 334 3 090 398 443 348 Volume
+6.67% -0.59% +0.52% +3.75% +4.68% Change
More quotes
Company
SkyePharma Plc is a UK based pharmaceutical company.It engages in the research and development, licensing, manufacturing, marketing and distribution of prescription pharmaceutical products.The company approves products in the areas of oral, inhalation and topical delivery.SkyePharma was founded by... 
Sector
Pharmaceuticals
Calendar
-
Surperformance© rating of SkyePharma PLC
Trading Rating : Investor Rating :
More about the company
Chart SKYEPHARMA PLC
Duration : Period :
SkyePharma PLC Technical Analysis Chart | SKP | GB00B3BFNB64 | 4-Traders
Full-screen chart
Financials ( GBP)
Sales 2014 76,2 M
EBIT 2014 21,3 M
Net income 2014 -0,16 M
Finance 2014 6,98 M
Yield 2014 -
Sales 2015 102 M
EBIT 2015 31,9 M
Net income 2015 24,8 M
Finance 2015 32,1 M
Yield 2015 -
PER 2014 -
PER 2015 12,96
EV / Sales 2014 4,76x
EV / Sales 2015 3,32x
Capitalization 369 M
More Financials
Latest news on SKYEPHARMA PLC
10/09 SKYEPHARMA : Says Sales Momentum Has Continued Since August
09/08 SKYEPHARMA : Partner Announces Phase III Flutiform Study Results
08/27 SKYEPHARMA : announces Interim Results 2014
08/23 SKYEPHARMA : Holding(s) in Company
08/22 SKYEPHARMA : Reports Interim Results Statement
08/21 SKYEPHARMA : *Skyepharma H1 Pretax Loss GBP18.1M Vs Pretax Loss GBP1.6M
08/21 SKYEPHARMA : *Skyepharma Says Prospects Remain In Line With Its Expectations
08/21 SKYEPHARMA : *Skyepharma H1 Revenue GBP34.4M Vs GBP31.3M
08/15 SKYEPHARMA : Acquires a novel inhaled therapy platform
07/23 SKYEPHARMA : Holding(s) in Company
07/03 SKYEPHARMA : announces Full Year 2013 Results
06/07 SKYEPHARMA : Presents at Jefferies Global Healthcare Conference
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF